ECSP20004580A - Moduladores de moléculas pequeñas de sting humana - Google Patents
Moduladores de moléculas pequeñas de sting humanaInfo
- Publication number
- ECSP20004580A ECSP20004580A ECSENADI20204580A ECDI202004580A ECSP20004580A EC SP20004580 A ECSP20004580 A EC SP20004580A EC SENADI20204580 A ECSENADI20204580 A EC SENADI20204580A EC DI202004580 A ECDI202004580 A EC DI202004580A EC SP20004580 A ECSP20004580 A EC SP20004580A
- Authority
- EC
- Ecuador
- Prior art keywords
- small molecule
- molecule modulators
- human sting
- sting small
- compounds
- Prior art date
Links
- 150000003384 small molecules Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108010050904 Interferons Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención hace referencia a compuestos de fórmula (I): Los compuestos se pueden usar para modular la proteína estimuladora de genes de interferón (STING) y tratar enfermedades como el cáncer y las infecciones microbianas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201711021858 | 2017-06-22 | ||
GB1709959.9A GB2563642A (en) | 2017-06-22 | 2017-06-22 | Small molecule modulators of human STING |
IN201811014462 | 2018-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP20004580A true ECSP20004580A (es) | 2020-05-29 |
Family
ID=62816874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI20204580A ECSP20004580A (es) | 2017-06-22 | 2020-01-21 | Moduladores de moléculas pequeñas de sting humana |
Country Status (20)
Country | Link |
---|---|
US (1) | US11571423B2 (es) |
EP (1) | EP3642198B1 (es) |
JP (1) | JP7296954B2 (es) |
KR (1) | KR102628892B1 (es) |
AR (1) | AR114975A1 (es) |
AU (1) | AU2018288018C1 (es) |
BR (1) | BR112019027127A2 (es) |
CA (1) | CA3067257A1 (es) |
CL (1) | CL2019003793A1 (es) |
CO (1) | CO2020000562A2 (es) |
EC (1) | ECSP20004580A (es) |
IL (1) | IL271522B2 (es) |
MX (1) | MX2019015468A (es) |
PE (1) | PE20200696A1 (es) |
PH (1) | PH12019502870A1 (es) |
SG (1) | SG11201912397RA (es) |
TW (1) | TWI799426B (es) |
UA (1) | UA125730C2 (es) |
WO (1) | WO2018234808A1 (es) |
ZA (1) | ZA201908496B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL264049B2 (en) | 2016-07-06 | 2023-11-01 | Sperovie Biosciences Inc | Compounds, preparations and methods for treating the disease |
BR112019027127A2 (pt) | 2017-06-22 | 2020-07-07 | Curadev Pharma Limited | moduladores de sting humano de molécula pequena |
GB2574913A (en) * | 2017-06-22 | 2019-12-25 | Curadev Pharma Ltd | Small molecule modulators of human STING, conjugates and therapeutic applications |
WO2019046511A1 (en) | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE |
US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
WO2019051488A1 (en) | 2017-09-11 | 2019-03-14 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE |
KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
JP2021525706A (ja) | 2018-05-25 | 2021-09-27 | インサイト・コーポレイションIncyte Corporation | Sting活性化剤としての三環式複素環式化合物 |
US10875872B2 (en) | 2018-07-31 | 2020-12-29 | Incyte Corporation | Heteroaryl amide compounds as sting activators |
WO2020028565A1 (en) | 2018-07-31 | 2020-02-06 | Incyte Corporation | Tricyclic heteraryl compounds as sting activators |
US11596692B1 (en) | 2018-11-21 | 2023-03-07 | Incyte Corporation | PD-L1/STING conjugates and methods of use |
EP3946610A1 (en) | 2019-03-28 | 2022-02-09 | Lupin Limited | Macrocyclic compounds as sting agonists |
CN118108716A (zh) | 2019-04-30 | 2024-05-31 | 四川科伦博泰生物医药股份有限公司 | 苯并噻吩类化合物及其制备方法和用途 |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
AU2020291796B2 (en) * | 2019-06-12 | 2024-01-18 | Ryvu Therapeutics S.A. | Next-generation modulators of stimulator of interferon genes (STING) |
JP2022536755A (ja) * | 2019-06-14 | 2022-08-18 | アイエフエム デュー インコーポレイテッド | Sting活性に関連する状態を治療するための化合物および組成物 |
US20220259254A1 (en) | 2019-07-05 | 2022-08-18 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
BR112022001125A2 (pt) | 2019-07-22 | 2022-03-15 | Lupin Ltd | Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos |
US11370803B2 (en) | 2019-09-18 | 2022-06-28 | Takeda Pharmaceutical Company Limited | Heteroaryl plasma kallikrein inhibitors |
JP2022548696A (ja) | 2019-09-18 | 2022-11-21 | 武田薬品工業株式会社 | 血漿カリクレインインヒビター及びその使用 |
GEP20237572B (en) * | 2019-09-25 | 2023-11-27 | Pfizer | Polyheterocyclic modulators of sting (stimulator of interferon genes) |
JP2023513241A (ja) * | 2020-02-12 | 2023-03-30 | キュラデブ ファーマ ピーブイティー. リミテッド | 小分子stingアンタゴニスト |
EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | ONO Pharmaceutical Co., Ltd. | CANCER THERAPY METHODS |
CN115835856A (zh) | 2020-05-13 | 2023-03-21 | 麻省理工学院 | 聚合物微装置的组合物以及其在癌症免疫疗法中的用途 |
EP4192506A1 (en) | 2020-08-07 | 2023-06-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
WO2022169921A1 (en) * | 2021-02-04 | 2022-08-11 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
US11964978B2 (en) * | 2021-03-18 | 2024-04-23 | Pfizer Inc. | Modulators of STING (stimulator of interferon genes) |
WO2023017452A1 (en) * | 2021-08-11 | 2023-02-16 | Curadev Pharma Pvt. Ltd. | Small molecule urea derivatives as sting antagonists |
IL310705A (en) | 2021-08-11 | 2024-04-01 | Curadev Pharma Pvt Ltd | Small molecule STING antagonists |
WO2023210623A1 (ja) * | 2022-04-28 | 2023-11-02 | 株式会社エス・ディー・エス バイオテック | ハロアルキルスルホンアニリド化合物及びそれらを含有する除草剤 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US6855726B1 (en) | 1998-03-31 | 2005-02-15 | Warner-Lambert Company Llc | Quinolones as serine protease inhibitors |
GB0225833D0 (en) | 2002-11-06 | 2002-12-11 | Univ Leeds | Nucleic acid ligands and uses therefor |
US7417052B2 (en) | 2004-09-29 | 2008-08-26 | Sankyo Company, Limited | Phenylene derivative having tetrazole ring or thiazolidinedione ring |
US7601716B2 (en) * | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
US7935709B2 (en) * | 2006-07-17 | 2011-05-03 | Amgen Inc. | 2-quinazolinone compounds and methods of use |
TW200831498A (en) | 2006-10-13 | 2008-08-01 | Otsuka Pharma Co Ltd | Heterocyclic compound |
NZ582124A (en) | 2007-05-21 | 2012-07-27 | Reviva Pharmaceuticals Inc | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents |
US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
TW201030007A (en) | 2009-02-06 | 2010-08-16 | Gruenenthal Gmbh | Substituted spiro-amides as b1r modulators |
GB0922589D0 (en) * | 2009-12-23 | 2010-02-10 | Almac Discovery Ltd | Pharmaceutical compounds |
JP2014527511A (ja) | 2011-06-24 | 2014-10-16 | アムジエン・インコーポレーテツド | Trpm8拮抗剤及び治療におけるそれらの使用 |
JP6236068B2 (ja) | 2012-05-08 | 2017-11-22 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | RORγ活性を阻害し疾患を治療するためのテトラヒドロナフチリジンおよび関連二環式化合物 |
JP2016147807A (ja) | 2013-06-04 | 2016-08-18 | 日本理化学工業株式会社 | ヒドロキサム酸誘導体またはその塩 |
MX2017002985A (es) | 2014-09-10 | 2017-11-17 | Epizyme Inc | Inhibidores de smyd. |
WO2017040963A1 (en) | 2015-09-03 | 2017-03-09 | Forma Therapeutics, Inc. | [6,6] fused bicyclic hdac8 inhibitors |
US20170146519A1 (en) * | 2015-11-20 | 2017-05-25 | Oregon Health & Science University | Sting agonists and methods of selecting sting agonists |
JP2020524717A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドCuradev Pharma Limited | ヒトstingの小分子調節因子 |
JP2020524718A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドCuradev Pharma Limited | ヒトstingの複素環式小分子調節因子 |
GB2563642A (en) | 2017-06-22 | 2018-12-26 | Curadev Pharma Ltd | Small molecule modulators of human STING |
GB2572526A (en) * | 2017-06-22 | 2019-10-09 | Curadev Pharma Ltd | Heterocyclic small molecule modulators of human STING |
BR112019027127A2 (pt) | 2017-06-22 | 2020-07-07 | Curadev Pharma Limited | moduladores de sting humano de molécula pequena |
TW202016081A (zh) | 2018-06-21 | 2020-05-01 | 英商克拉德夫製藥有限公司 | 人類sting之小分子調節劑、結合物及治療應用 |
-
2018
- 2018-06-21 BR BR112019027127-9A patent/BR112019027127A2/pt unknown
- 2018-06-21 SG SG11201912397RA patent/SG11201912397RA/en unknown
- 2018-06-21 UA UAA202000289A patent/UA125730C2/uk unknown
- 2018-06-21 AU AU2018288018A patent/AU2018288018C1/en active Active
- 2018-06-21 TW TW107121352A patent/TWI799426B/zh active
- 2018-06-21 CA CA3067257A patent/CA3067257A1/en active Pending
- 2018-06-21 PE PE2019002587A patent/PE20200696A1/es unknown
- 2018-06-21 KR KR1020207001712A patent/KR102628892B1/ko active IP Right Grant
- 2018-06-21 JP JP2020520840A patent/JP7296954B2/ja active Active
- 2018-06-21 EP EP18737372.5A patent/EP3642198B1/en active Active
- 2018-06-21 MX MX2019015468A patent/MX2019015468A/es unknown
- 2018-06-21 US US16/625,047 patent/US11571423B2/en active Active
- 2018-06-21 WO PCT/GB2018/051730 patent/WO2018234808A1/en unknown
-
2019
- 2019-06-21 AR ARP190101730A patent/AR114975A1/es unknown
- 2019-12-18 PH PH12019502870A patent/PH12019502870A1/en unknown
- 2019-12-18 IL IL271522A patent/IL271522B2/en unknown
- 2019-12-19 ZA ZA2019/08496A patent/ZA201908496B/en unknown
- 2019-12-20 CL CL2019003793A patent/CL2019003793A1/es unknown
-
2020
- 2020-01-20 CO CONC2020/0000562A patent/CO2020000562A2/es unknown
- 2020-01-21 EC ECSENADI20204580A patent/ECSP20004580A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR102628892B1 (ko) | 2024-01-24 |
EP3642198A1 (en) | 2020-04-29 |
PE20200696A1 (es) | 2020-06-16 |
AU2018288018C1 (en) | 2022-10-20 |
EP3642198B1 (en) | 2022-03-16 |
IL271522A (en) | 2020-02-27 |
TWI799426B (zh) | 2023-04-21 |
IL271522B2 (en) | 2023-07-01 |
KR20200031616A (ko) | 2020-03-24 |
TW201920120A (zh) | 2019-06-01 |
MX2019015468A (es) | 2020-08-03 |
ZA201908496B (en) | 2021-04-28 |
CA3067257A1 (en) | 2018-12-27 |
CO2020000562A2 (es) | 2020-01-31 |
US20200147083A1 (en) | 2020-05-14 |
US11571423B2 (en) | 2023-02-07 |
AU2018288018B2 (en) | 2022-04-14 |
SG11201912397RA (en) | 2020-01-30 |
AR114975A1 (es) | 2020-11-11 |
UA125730C2 (uk) | 2022-05-25 |
CL2019003793A1 (es) | 2020-08-07 |
IL271522B1 (en) | 2023-03-01 |
CN111132972A (zh) | 2020-05-08 |
JP7296954B2 (ja) | 2023-06-23 |
AU2018288018A1 (en) | 2020-01-16 |
WO2018234808A1 (en) | 2018-12-27 |
BR112019027127A2 (pt) | 2020-07-07 |
JP2020524719A (ja) | 2020-08-20 |
PH12019502870A1 (en) | 2020-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP20004580A (es) | Moduladores de moléculas pequeñas de sting humana | |
CO2021008224A2 (es) | Inhibidores de kif18a | |
BR112018073861A2 (pt) | métodos de terapia de genes para doenças e condições relacionadas com a idade | |
ECSP20069418A (es) | Compuestos heterocíclicos como inmunomoduladores | |
MX2021007104A (es) | Inhibidores de kif18a. | |
CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
SA519401435B1 (ar) | مركبات حلقية ثنائية النيوكليوتيد | |
CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
CO2018010504A2 (es) | Inhibidores del enlace proteína-proteína de wdr5 | |
ECSP17073191A (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
UY35827A (es) | Derivados de triazolopirazina como inhibidores de la proteína brd4 | |
DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
CL2019003515A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina. | |
CL2021001198A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
CO2020016131A2 (es) | Agonistas de tlr7 | |
DOP2021000021A (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
UY37622A (es) | Derivados de pirazol como inhibidores de bromodominio de la familia bet y su uso en aplicaciones terapéuticas | |
CL2020000127A1 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa. | |
BR112017016883A2 (pt) | compostos com atividade antitumoral | |
ECSP22049906A (es) | Agonistas del tlr7 | |
EA202090092A1 (ru) | Низкомолекулярные модуляторы sting человека |